Jazz Pharmaceuticals
Jazz Pharmaceuticals · page 2
- Markets & Stocks
CanG’s Passage Drives Up Global Cannabis Stock Prices, & Jazz Pharma Pays $7.5m To Settle Lawsuit Over GW Acquisition
Germany’s passage of CanG continues to drive up stock prices Yesterday, the President of Bundesrat, Manuela Schwesig, signed Germany’s landmark CanG bill, meaning it is now all but certain to be brought into law on April 01.
- Markets & Stocks
IMC Could Become Latest To Exit Cannabis Space, Jazz Pharma Reports $900m In 2023 Epidyolex Sales, & More From DanCann Pharma
IM Cannabis IM Cannabis has become the latest major Israeli cannabis company to announce potential plans to depart the industry altogether and sell off its remaining assets.
- Uncategorized
Teva Pharmaceuticals Fails to Disqualify Jazz Pharmaceuticals’ Epidyolex Patent In Court
Jazz Pharmaceuticals has rebuffed attempts by rival Teva Pharmaceuticals to legally disqualify its patent for Epidyolex, a cannabis-based drug worth hundreds of millions of dollars a year.
- Markets & Stocks
Jazz Pharma’s Epidiolex Approved in Canada, Apollon Nears Take Over Deal, & Stenocare Expands in Australia
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU and UK), Jazz Pharmaceuticals’ market leading cannabis-based medication, has received authorisation to be prescribed for a number of conditions in Canada.
- CBD Market
Japan Takes Major Step Towards Cannabis Reform
Japan, one of the world’s strictest and most hostile countries in regard to cannabis, recently took a major step towards reform, potentially providing a major boom for the country’s CBD industry and opening the door for the establishment of a medical cannabis and industrial hemp industry in the country.
- Data & Analysis
Pharma Industry Showing ‘Growing Interest’ in Cannabis as M&A Activity Increases
Big pharma has so far been cautious of diving headfirst into the cannabis industry, despite the growing body of evidence surrounding its medical benefits.
- Markets & Stocks
German Cannabis Stocks Jump on Passage of Draft Adult-Use Bill, More from Jazz Pharma & Ananda Developments
German Stocks Spike on Passage of Draft Law [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”SBX.DE” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Synbiotic SE (SBX) Yesterday, the German federal cabinet officially passed the draft law which would seek to implement Pillar 1 of the country’s ambitious adult-use cannabis legalisation strategy.
- Data & Analysis
Pharmaceutical Cannabis Industry Sales to Grow 20% to $1.37bn by 2027, According to New Report
Pharmaceutical cannabis industry sales are expected to grow by over 20% over the next four years, from $1.14b to $1.37b by 2027.
- Markets & Stocks
European Cannabis Stocks Review: Northern Leaf Seeks Funding For IPO, MGC Reports ‘Strongest Half-Year To Date’, & More From Jazz Pharmaceuticals
Northern Leaf Jersey-based medical cannabis cultivator Northern Leaf is reportedly aiming to raise a further £3m in pre-IPO funding with a view to going public later this year.
- Pharmaceutical
Has GW Pharmaceuticals – Now Jazz Pharmaceuticals – Knee-Capped The CBD Industry?
WITH the fast-growing CBD sector tied up in a regulatory quagmire hundreds of transatlantic industry players face an uncertain future.
